依达拉奉对急性脑梗死患者血管性血友病因子和超敏C反应蛋白的影响

Influence of edaravone on the serum levels of vWF and hs-CRP in patients with acute cerebral infarction

目的研究依达拉奉对急性脑梗死患者血管性血友病因子(vWF)及超敏C反应蛋白(hs-CRP)的影响并探讨其作用机制。方法40例急性脑梗死患者随机分成两组,常规治疗组(银杏达莫20ml,1次/d,连续14d,静脉点滴);依达拉奉组(依达拉奉注射液30mg,2次/d,连续14d,静脉点滴),同期选择非脑血管病患者20例作为对照组。检测治疗前和治疗后7d患者血浆vWF及血清hs-CRP浓度的变化,测定治疗5d内头部MRI所示病灶大小,测定治疗前、治疗第30d的NIHSS评分,判定两组的疗效。结果在治疗7d,依达拉奉组的vWF浓度明显低于常规治疗组(P<0.01)。治疗7d时,与常规治疗组相比,依达拉奉组hs-CRP浓度下降明显(P<0.01)。依达拉奉组治疗的有效率及显效率明显高于常规治疗组(P<0.05)。与腔隙性、小面积脑梗死组比较,中面积及大面积脑梗死组的治疗前hs-CRP浓度明显升高(P<0.05)。结论依达拉奉能够直接降低血清vWF和hs-CRP的浓度,这可能是其治疗急性脑梗死的机制之一。

Objective To study the influence of edaravone on the serum levels of vWF and hs-CRP in patients with acute cerebra2 infarction. Methods 40 patients with acute cerebral infarction were randomly divided into routine group of 20 eases and edaravone group of 20 cases. All cases were given routine treatment, while the cases of edaravone group were added with edaravone 30mg, twice a day, total1y14d. The serum levels of vWF and hs-CRP were investigated before and 7d after treatment and the sizes of the infarction on MRI were measured on 5d after treatment. The NIH scale and clinical outcome were evaluated before and 30d after treatment. Results The therapeutic efficacy of edaravone group was significantly better than that of routine group （P 〈 0. 05 ）. The serum levels of vWF of the edaravone group were lower than those of routine group on 7d（P 〈0.01 ）. Compared with control group,the serum levels of hs-CRP were the lowest on 7d（P 〈0.01 ）. The hs-CRP levels of middle and large infarction groups before treatment were higher than those of lacunar and small infarction groups （ P 〈 0.05 ）. Conclusion Our result indicates that edaravone can reduce the injury of ischemic brain cells and improve therapeutic efficacy probably through decreasing the serum level of vWF and hs-CRP.